HeartBeam Reports Q3 2026 Earnings with Reduced Operating Expenses and Improved Cash Guidance
HeartBeam, Inc. (BEAT) reported its third-quarter 2026 financial results, highlighting a significant reduction in operating expenses and improved cash management. The company achieved a 35% year-over-year decline in operating expenses to $3.5 million following the completion of primary development for the HeartBeam System. Net loss for the first nine months of the year narrowed to $12.7 million, down from $15.7 million in the prior year period. Strategically, the company is focusing on heart attack detection and has confirmed a 510(k) regulatory pathway with the FDA. HeartBeam's proprietary 3D ECG technology demonstrated high clinical performance metrics, including 97% accuracy for its Atrial Flutter algorithm. The company plans to initiate a U.S. pivotal study involving approximately 300 patients, with enrollment expected to begin in late 2026 or early 2027 and conclude by mid-2027.
Topics: financial guidance operating cash flow product performance R&D spending